

Recombinant HMPV B Fusion Glycoprotein F0, His-tagged

Product Information

Cat#

HUM-420

Product Name

Recombinant HMPV B Fusion Glycoprotein F0, His-tagged

Description

Human metapneumovirus glycoprotein F0. The protein was produced in HEK293 cells and purified from culture supernatant. The F glycoprotein mediates virus-cell membrane fusion and is the primary target of neutralizing antibodies.

Туре

Recombinant

Gene

Fusion Glycoprotein F0

Species

HMPV

Source

HEK293

Synonyms

hMPV B Fusion Glycoprotein F0

Formulation

PBS

Notes

This product is intended for research and manufacturing uses only. It is not a diagnostic device. The user assumes all responsibility for care, custody and control of the material, including its disposal, in accordance with all regulations.

Tel: 1-631-559-9269 1-516-512-3133



Recombinant HMPV B Fusion Glycoprotein F0, His-tagged

Tags

His

Background

Human metapneumovirus (hMPV) is an enveloped, negative-sense, single-stranded RNA virus belonging to the genus Metapneumoviridae, of the family Pneumoviridae. hPMV is closely related to Respiratory Syncytial virus (RSV), which belongs to the genus Orthopneumovirus within the same family (Alfonso et al., 2016). Human metapneumovirus is globally widespread and spreads seasonally in temperate climates. Genomic analysis has shown that hMPV exists as two genotypes (A and B), which are further divided into the subgroups A1, A2, B1 and B2. Each subgroup has a distinct geographical distribution but can circulate separately or concurrently (Boivin et al., 2004). Transmission of HPMV from person-to-person predominantly occurs through contact with airborne droplets from an infected individual, produced by coughing or sneezing. It can also be spread through contact with contaminated hands or surfaces. Serosurveillance studies have shown that most children worldwide are infected with hMPV by the age of 5 (Shafagati et al., 2018). Rates of hospitalization of children for hMPV infection are highest in the first year of life but continue to occur throughout early childhood. Studies have tended to suggest that the peak age of hospitalization for MPV is between 6 and 12 months of age, which is later than the peak age of hospitalization for RSV (2–3 months).

Tel: 1-631-559-9269 1-516-512-3133